|
On (b)(6) 2022, abbott point of care was contacted by a customer regarding act celite cartridges that yielded discrepant results on a patient.There was no patient information available at the time of this report.Return product is available for investigation.The customer states that results did not correspond with clinical picture as dosage of heparin administered to patient did not increase the act result.Result (sec):.231.Baseline, 261, 237, 249, heparin dosage: 11000, 3000, 3000.Note: there were no collection/test times provided, nor were there times provided for heparin doses administered to the patient.At this time there is no reason to suspect a malfunction exists.No reports of delay or impact to patient management.The reporting decision was based on the limited information available that suggests the product was not performing within the variability of the assay.An investigation is underway.Per i-stat system manual ((b)(4)), the intended use of the i-stat celite activated clotting time (celite act) test is an in vitro diagnostic test that uses fresh, whole blood, and is useful for monitoring patients receiving heparin for treatment of pulmonary embolism or venous thrombosis, and for monitoring anticoagulation therapy in patients undergoing medical procedures such as catheterization, cardiac surgery, surgery, organ transplant, and dialysis.
|